Was Britain’s Infected Blood Scandal Really About American Blood?

By The Unheard Voice

For decades, one explanation of the infected blood scandal has become deeply familiar.

Britain could not produce enough blood products.

Products were imported from America.

Some American donors were paid.

Some came from populations with a higher prevalence of blood-borne viruses.

Thousands of people in Britain were infected.

Those facts form part of the history.

But they are not the whole history.

And one apparently simple phrase — “infected American blood” — can blur several very different stories together.

A House of Lords Library briefing states that during the 1970s the NHS sourced around 50% of its “blood and blood-derived products” from abroad, including the United States.

It also records that the government committed in 1975 to making the NHS self-sufficient in blood supplies, but that this objective was not achieved as demand for blood products increased.

Read quickly, however, that statistic can leave a misleading impression.

Whole blood, plasma and manufactured clotting-factor concentrates are not the same thing.

For people with haemophilia and other bleeding disorders, one of the most important developments of the 1970s was the increasing use of concentrated clotting factors such as Factor VIII.

These products transformed treatment.

But their manufacture required plasma from large numbers of donors to be pooled together.

That created a serious vulnerability.

If plasma from an infected donor entered a large pool, the resulting product could expose many recipients.

As demand for Factor VIII increased, Britain became heavily dependent on imported commercial concentrates.

That is where the American story becomes particularly important.

Commercial plasma collection in the United States included paid donation.

Some manufacturers also sourced plasma from groups recognised as presenting greater infection risks, including prison populations.

But focusing only on the geographical origin of that plasma risks missing a crucial part of what the Infected Blood Inquiry eventually established.

The scandal was not simply something America did to Britain.

The Inquiry examined decisions made within Britain about which products were licensed, purchased and used.

It examined how risks were assessed.

How patients were warned.

How blood and blood products were administered.

And how government and public bodies responded as evidence of infection accumulated.

Those decisions matter.

So does Britain’s failure to become self-sufficient.

The House of Lords Library records that the government committed in 1975 to achieving NHS self-sufficiency by July 1977, but the target was not met.

Britain continued to rely on imported products as domestic processing capacity struggled to meet demand.

And there is another danger in reducing the entire scandal to imported American products.

Not everyone infected through NHS treatment had haemophilia.

Thousands of people received ordinary blood transfusions.

The Inquiry’s findings on transfusion practice are striking.

It concluded that during the 1970s, 1980s and beyond, some patients were given blood unnecessarily or were given more blood than necessary, despite long-standing medical awareness that transfusion carried infection risks.

The Inquiry described an unacceptable complacency about blood safety and concluded that earlier action could have reduced infections and, in all likelihood, saved lives.

That cannot be explained simply by pointing towards America.

Nor can the failures to warn patients properly.

The Inquiry found a widespread failure to explain transfusion risks and alternatives to patients when such warnings could reasonably have been given.

When the Inquiry’s final report was published on 20 May 2024, the then Prime Minister did not describe what had happened merely as the consequence of contaminated imports.

He called it a “day of shame for the British state.”

His statement acknowledged what Sir Brian Langstaff had described as systemic, collective and individual failures involving the NHS, government and other institutions over decades.

That distinction is important.

The provenance of plasma matters.

Paid donation matters.

Commercial manufacturing matters.

The use of high-risk donor populations matters.

But so do the decisions taken after those products reached Britain.

So do the decisions about domestic production.

Licensing.

Procurement.

Clinical practice.

Warnings.

Testing.

Information.

And government response.

The Infected Blood Inquiry did not reduce this catastrophe to one contaminated product arriving from one foreign country.

Its final report spans seven volumes examining what happened across treatment, blood services, government, healthcare institutions and public bodies.

So perhaps we need to be more careful about the question we ask.

Instead of simply asking:

Where did the infected blood come from?

We should also ask:

What was actually imported?

Who understood the risks?

Who had the power to change course?

What decisions were taken in Britain?

And why were patients still exposed?

The American plasma story is real.

But it is only part of the infected blood story.

And if we reduce one of Britain’s greatest healthcare scandals to the phrase “infected blood from America”, we risk overlooking the very thing the public inquiry spent years establishing:

what happened was also the result of failures within Britain itself.

— The Unheard Voice